Cell line development platform for SMEs to reduce the length and cost of biologic drug development

Projektinformationen

IcoCell

ID Finanzhilfevereinbarung: 718711

DOI 10.3030/718711

Projekt abgeschlossen

EK-Unterschriftsdatum 5 April 2016

Startdatum 1 Mai 2016

Enddatum 31 August 2018

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Gesamtkosten € 1 614 000,00

EU-Beitrag € 1 129 800,00

Koordiniert durch

ICOSAGEN CELL FACTORY OU
Estonia

Ziel

Biologic drugs ($160+ billion market) provide better long-term health outcomes with fewer side effects than many traditional drugs. However, due to high development and production costs, these drugs are 20x more expensive, on average, limiting the access to these therapies and burdening healthcare systems. To a great extent, this is because traditionally flexible and creative biotech SMEs currently lack rational tools for mammalian cell line development (most of the biologic drugs are produced in mammalian cell lines), meaning that large investment in terms of capital and time is required to make a production cell line.

ICF, an established player in the biotechnology industry, develops a technology for more efficient development of mammalian cell lines for high-yield protein production. It reduces the need for robotic systems and high-throughput screening facilities (€900 000 -> €200 000), the time (6-12 months -> 3) and cost (€100 000 -> €50 000) of cell line development. These advantages stem from specific landing platforms, predefined integration sites, recombination-dependent insertion and amplification of expression units. The technology will enable biotech SMEs to develop the process of production of new biologic drugs at lower costs and faster, eventually enabling biologic drugs to penetrate more cost-sensitive indications and target groups.

IcoCell project is aimed at optimizing the landing platform, generating cell lines compatible with process of development of industrial cell factories, generating regulatory documentation, preparing standard operating procedures, demonstrating the production of different types of proteins and implementing initial exploitation activities.

Cell line development market is expected to grow at CAGR of 12.8% (2014-2022) and the market for cell line development to produce therapeutic proteins exceeds €900M. Commercialization of IcoCell technology will mean breakthrough for ICF, increasing revenues by an estimated €26M in 2021

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• social sciences › economics and business › business and management › innovation management
• natural sciences › biological sciences › genetics › DNA
• natural sciences › biological sciences › biochemistry › biomolecules › proteins

Programm/Programme

• H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• BIOTEC-5b-2015 - SME boosting biotechnology-based industrial processes driving competitiveness and sustainability

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2015

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

ICOSAGEN CELL FACTORY OU

• Netto-EU-Beitrag: € 1 129 800,00
• Adresse: EERIKA TEE 1 ; 61713 Kambja Vald ; Estland
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Eesti › Eesti › Lõuna-Eesti
• Region: Eesti › Eesti › Lõuna-Eesti
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 1 614 000,00